New Horizons in Pustular Psoriasis: Will You Be Ready?

Scroll to the Bottom of this Information to Begin this Course

Sponsored by The Academy for Continued Healthcare Learning (ACHL).

 

Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Credit Available

• Physicians — maximum of 0.75 AMA PRA Category 1 Credit(s)™

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is intended for dermatologists, primary care providers, nurse practitioners, and physician assistants who treat patients with pustular psoriasis.

Program Overview

Clinicians must be ready to translate rapidly evolving guidance and emerging science to improve outcomes for their patients. Dr. Mark Lebwohl from the Icahn School of Medicine at Mount Sinai recently hosted several small-group CME Meet-Up’s. This recorded meet-up discusses:

• the lack of U.S. guidance that complicates diagnosis and disease assessment
• the most recent pathophysiologic findings for pustular psoriasis and implications for treatment
• the latest safety and efficacy data for new and emerging agents for pustular psoriasis

Learning Objectives

Upon completion of this activity, participants should be able to:

• Assess patients with pustular psoriasis, based on clinical manifestations, diagnostic criteria, and disease severity.
• Discuss the pathophysiology of pustular psoriasis, including how it differs from that of plaque psoriasis and potential pathways for therapeutic targets.
• Review the clinical profiles and mechanisms of action of new and emerging biologic treatment options for adults with PPP and GPP.

Faculty

Physician Continuing Medical Education

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

 

Credit Designation

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completing as AANP accepts AMA PRA Category 1 Credit(s)™ through its reciprocity agreements.)

Disclosures of Conflicts of Interest

The Academy for Continued Healthcare Learning (ACHL) requires the faculty participating in an accredited continuing education activity to disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Mark Lebwohl, MD, (Chair)

• Consultant: Aditum Bio, Almirall, AnaptysBio, Arcutis Biotherapeutics, Aristea Therapeutics, Arrive Technologies, Inc., Avotres Therapeutics LLC, BiomX Inc., Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Castle Biosciences, Corrona, LLC, Dermavant Sciences, Dr. Reddy's Laboratories Ltd., Evelo Biosciences, Evommune, Inc., Facilitation of International Dermatology Education, Forte Biosciences Inc., Foundation for Research and Education in Dermatology, Helsinn Therapeutics, LEO Pharma Inc., Meiji Seika Pharma Co., Ltd., Mindera Consultant, Pfizer Inc., Verrica Pharmaceuticals
• Research Funds: Abbvie, Amgen, Arcutis Biotherapeutics, Avotres Inc., Boehringer Ingelheim, Dermavant Sciences, Eli Lilly and Company, Incyte, Janssen Research & Development, LLC, Ortho Dermatologics, Inc., Regeneron Pharmaceuticals, UCB

Staff and Reviwers Disclosures

ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

Instructions for Participation and Credit

This activity will take approximately 45-minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions about this activity, please contact Michelle Forcier at mforcier@achlcme.org.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure of Unlabeled Use

This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use

Systemic corticosteroids, acitretin, cyclosporine A, methotrexate, infliximab, adalimumab, etanercept, psoralen plus ultraviolet A, aprelimast, certolizumab pegol, ustekinumab, guselkumab, secukinumab, ixekizumab, brodalumab, isotretinoin for pustular psoriasis. Discussion of investigational spesolimab and imsidolimab for pustular

Disclaimer

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

For CME questions please contact mforcier@achlcme.org.